ArticleDrug metabolism and disposition: the biological fate of chemicals2025
Metabolic activation of flunitrazepam via nitroreduction mediated by aldo-keto reductase 1C3.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Aldo-keto reductases (AKRs) are a superfamily of NAD(P)(H)-dependent oxidoreductases (phase I enzymes) that reduce aldehydes and ketones to primary and secondary alcohols, respectively. Four percent of xenobiotic biotransformation has been attributed to AKRs, although this is likely an underestimate because this is based on their ability to act as carbonyl reductases. AKRs also have an emerging role in nitroreduction. We screened 6 nitro-containing drugs (flunitrazepam, clonazepam, nimesulide, nilutamide, flutamide, and chloramphenicol) as substrates against recombinant human AKR1C1, AKR1C2, AKR1C3, and AKR1C4, using discontinuous enzymatic assays. AKR1C3 was able to reduce flunitrazepam to 7-amino-flunitrazepam. Metabolites formed during the reaction were identified by tandem mass spectrometry, which confirmed the formation of nitroso and hydroxylamino intermediates. The role of AKR1C3 was confirmed in HepG2 cells since AKR1C3-specific inhibitors blocked the formation of 7-amino-flunitrazepam. Interestingly, clonazepam (which lacks the tertiary amide of flunitrazepam) was not metabolized by AKR1C3. Molecular docking and dynamics simulations indicated that residue 120 (methionine) in AKR1C3 plays an important role in flunitrazepam-protein binding. Our computational approach suggested that the interaction between the flunitrazepam and AKR1C1, AKR1C2, and AKR1C4 is unlikely to occur and supported our experimental results. Our findings show that AKR1C3 can reduce flunitrazepam to reactive nitroso intermediates that could enhance drug toxicity and that flunitrazepam inhibits AKR1C2, which is responsible for the formation of the neuroactive steroid allopregnanolone. We conclude that both AKR1C3 and AKR1C2 may have an important role in flunitrazepam drug response. SIGNIFICANCE STATEMENT: Aldo-keto reductase (AKR)1C3 reduces flunitrazepam to 7-amino-flunitrazepam through the formation of reactive nitroso and hydroxylamino intermediates, and by inhibiting AKR1C2, flunitrazepam may reduce the formation of the neuroactive steroid allopregnanolone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.